present
studi
evalu
effect
age
induct
syngen
graftversushost
diseas
sgvhd
syngen
bone
marrow
transplant
bmt
cyclosporin
csa
therapi
result
clearli
document
invers
correl
age
incid
sgvhd
virtual
incid
sgvhd
occur
lewi
rat
syngen
bmt
csa
therapi
start
anim
wk
age
thereaft
dramat
declin
incid
sgvhd
increas
age
anim
although
age
recipi
import
signific
effect
age
marrow
donor
marrow
anim
mo
age
virtual
incap
elicit
sgvhd
bmt
csa
therapi
furthermor
mix
marrow
matur
immatur
anim
result
decreas
incid
sgvhd
implic
regulatori
effect
present
marrow
older
rat
regulatori
effect
due
presenc
matur
cell
marrow
anim
mo
age
despit
fact
marrow
young
anim
possess
matur
lymphocyt
regulatori
activ
absent
suggest
host
resist
mediat
lymphocyt
develop
anim
age
data
implic
import
host
resist
mechan
prevent
induct
sgvhd
csa
appear
mediat
clonal
inactiv
autoreact
cell
c
yclosporin
csa
l
potent
immunosuppress
agent
appar
select
action
lymphocytedepend
immun
respons
use
extens
clinic
transplant
prevent
solid
organ
allograft
reject
graftversushost
diseas
gvhd
csa
current
evalu
therapeut
agent
treatment
ofautoimmun
diseas
result
trial
appear
quit
promis
despit
potent
immunosuppress
activ
csa
therapi
autolog
syngen
bone
marrow
transplant
paradox
elicit
cellmedi
autoimmun
syndrom
patholog
ident
gvhd
occur
allogen
bone
marrow
transplant
bmt
henc
csainduc
autoimmun
syndrom
origin
term
syngen
gvhd
sgvhd
immunobiolog
sgvhd
complex
complet
understood
appear
due
uncoupl
normal
immunolog
homeostasi
involv
selfnonself
recognit
abbrevi
use
paper
bmt
bone
marrow
transplant
cce
counterflow
centrifug
elutri
csa
cyclosporin
gvhd
graftversushost
diseas
ro
rotoroff
sgvhd
syngen
gvhd
autoimmun
diseas
occur
cessat
csa
therapi
mediat
lymphocyt
intim
associ
appear
autocytotox
cell
recogn
public
epitop
class
ii
major
histocompat
antigen
th
cell
subset
also
play
essenti
role
diseas
manifest
studi
suggest
lymphocytedepend
host
resist
mechan
must
elimin
develop
autoaggress
syndrom
occur
addit
import
recent
find
indic
addit
thymic
irradi
csa
treatment
age
critic
variabl
induct
sgvhd
anim
mo
age
much
resist
induct
autoimmun
csa
mechan
account
resist
matur
anim
unknown
may
relat
lack
ofa
pronounc
effect
csa
thymic
medulla
postul
beschorn
et
al
hand
recent
evid
suggest
increas
number
ofautoregulatori
cell
older
anim
thu
prevent
clonal
amplif
autoreact
cell
present
studi
demonstr
signific
correl
age
induct
sgvhd
virtual
incid
occur
anim
wk
age
time
transplant
thereaft
incid
rapidli
decreas
age
surprisingli
age
marrow
donor
much
critic
variabl
induct
sgvhd
age
recipi
furthermor
evid
provid
inabl
induc
sgvhd
use
marrow
donor
mo
age
due
marrowderiv
matur
lymphocyt
addit
cell
marrow
anim
mo
age
inhibit
induct
sgvhd
rat
lewi
femal
rt
rat
corona
viru
free
mo
age
neonat
thymectom
lewi
femal
rat
purchas
charl
river
breed
laboratori
wilmington
kept
steril
microisol
cage
totalbodi
irradi
lewi
rat
irradi
day
rad
radsmin
dual
sourc
small
anim
irradi
atom
energi
canada
ltd
kanata
ontario
canada
bone
marrow
transplant
donor
viralfre
lewi
rat
kill
asphyxi
marrow
collect
femur
tibia
humeri
rpmi
marrow
cell
adjust
concentr
x
nucleat
cellsml
infus
recipi
anim
intraven
inject
dorsal
tail
vein
day
total
volum
inject
ml
antibiot
rat
receiv
medic
drink
water
supplement
bactrim
neomycin
polymyxin
b
previous
describ
csa
csa
gener
gift
sandoz
ltd
basel
switzerland
powder
csa
dissolv
ethanol
ad
emulphor
solut
deioniz
rat
weigh
daili
receiv
g
subcutan
day
marrow
infus
consecut
day
total
dose
csa
per
day
per
rat
either
mgkg
control
anim
receiv
ident
quantiti
drug
diluent
ethanol
emulphor
hzo
without
csa
assess
sgvhd
rat
examin
daili
sign
clinic
gvhd
ear
biopsi
taken
frequent
interv
initi
onset
sgvhd
occur
within
discontinu
csa
therapi
present
acut
gvhd
erythema
dermat
within
wk
onset
diseas
progress
chronic
type
gvhd
alopecia
fibrosi
anim
follow
wk
discontinu
csa
therapi
assess
either
delay
appear
diseas
resolut
diseas
progress
develop
extens
diseas
upon
develop
chronic
diseas
anim
kill
previous
describ
criteria
use
histolog
document
gvhd
acut
sgvhd
defin
presenc
dyskeratot
cell
vacuolar
degener
lymphocyt
exocytosi
epiderm
destruct
vascular
chang
basal
layer
dyskeratot
cell
lymphocytec
dermal
andor
epiderm
infiltr
anim
extens
diseas
kill
autopsi
perform
skin
tongu
liver
intestin
spleen
histolog
examin
presenc
gvhd
histolog
examin
diagnosi
sgvhd
perform
observ
blind
experiment
protocol
cell
separ
counterflow
centrifug
elutri
use
separ
bone
marrow
cell
basi
cell
size
densiti
previous
describ
techniqu
allow
separ
rel
distinct
cell
popul
enrich
lymphocyt
contain
marrow
briefli
x
bone
marrow
cell
suspend
ml
elutri
medium
salin
bsa
mm
edta
ph
inject
inlet
stream
lead
centrifug
equip
elutri
rotor
standard
chamber
beckman
instrument
palo
alto
ca
cell
load
chamber
flow
rate
mlmin
rotor
speed
rpm
g
temperatur
rotor
speed
held
constant
cell
elut
chang
flow
rate
case
rat
bone
marrow
lymphocyt
purg
flow
rate
mlmin
collect
intermedi
size
cell
mlmin
ml
cell
still
remain
elutri
chamber
collect
continu
medium
flow
stop
rotor
design
rotoroff
fraction
cell
wash
resuspend
rpmi
mah
murin
antibodi
direct
rat
lymphocyt
determin
purchas
serotec
bioproduct
scienc
inc
indianapoli
specif
mab
ascit
fluid
use
studi
consist
panspecif
rat
lymphocyt
specif
rat
th
cell
identifi
rat
nonth
cell
subset
detect
antigen
specif
k
l
chain
immunomagnet
separ
bone
marrow
cell
normal
anim
first
separ
counterflow
centrifug
elutri
cce
deplet
specif
subset
immunolog
separ
use
immunomagnet
bead
coat
commerci
coval
bound
affinitypurifi
fcspecif
sheep
polyclon
ig
mous
subclass
dynabead
dynal
inc
great
neck
ny
previous
describ
briefli
x
cell
incub
satur
concentr
primari
antibodi
min
end
incub
supernat
remov
cell
thoroughli
wash
pb
bsa
three
time
cell
incub
microspher
one
cellfiv
bead
min
hematolog
mixer
remov
unbound
cell
suspens
tube
held
near
magnet
particl
concentr
p
biochem
inc
gaithersburg
md
minut
nonadher
popul
remov
pasteur
pipet
posit
select
cell
complex
microspher
local
magnet
fluid
flow
microjiuorimetri
analysi
type
cell
separ
list
deplet
popul
stain
fitc
conjug
primari
antibodi
use
deplet
fitc
conjug
mab
reciproc
subset
isotypespecif
fitc
sheep
antimous
igg
detect
residu
cell
coat
primari
antibodi
use
select
singl
immunofluoresc
analyz
facscan
analyt
scanner
hewlettpackard
co
alto
ca
neg
select
popul
less
contamin
deplet
cell
subset
averag
statisticalanalysi
result
analyz
multivari
analysi
xa
test
effect
ofag
induct
sgvhd
initi
studi
undertaken
assess
effect
age
induct
sgvhd
lewi
rat
treat
c
syngen
marrow
transplant
anim
mo
age
irradi
reconstitut
marrow
similarli
age
marrowderiv
lymphocyt
syngen
graftversushost
diseas
syngen
donor
respect
treat
grade
dose
csa
result
fig
demonstr
signific
effect
age
induct
sgvhd
transplant
lewi
rat
demonstr
virtual
incid
sgvhd
treat
mg
csa
incid
observ
anim
treat
mgkg
drug
contrast
moder
incid
sgvhd
observ
anim
transplant
mo
age
highest
dose
csa
test
minim
incid
sgvhd
observ
rat
initi
transplant
mo
age
seri
experi
perform
analyz
effect
age
induct
sgvhd
separ
marrow
donor
recipi
basi
age
studi
design
assess
whether
donor
andor
host
age
factor
influenc
frequenc
sgvhd
induc
csa
lewi
rat
either
mo
age
use
donor
bone
marrow
lethal
irradi
recipi
reciproc
experi
perform
lewi
rat
serv
recipi
bone
marrow
rat
recipi
treat
grade
dose
csa
irradi
bone
marrow
reconstitut
fig
illustr
signific
p
x
correl
age
marrow
donor
induct
sgvhd
recipi
greatest
frequenc
sgvhd
observ
anim
graft
marrow
rat
mo
age
marrow
deriv
anim
mo
age
result
decreas
incid
sgvhd
compar
age
recipi
also
correl
p
abil
csa
induc
sgvhd
youngest
recipi
greatest
incid
sgvhd
effect
dose
csa
intim
associ
donor
age
recipi
age
howev
lower
dose
csa
administ
recipi
studi
fig
b
reflect
less
dramat
declin
incid
addit
studi
summar
fig
assess
figur
effect
age
induct
sgvhd
grade
dose
csa
lewi
rat
mo
age
irradi
graft
marrow
similarli
age
syngen
rat
respect
recipi
treat
grade
dose
c
incid
sgvhd
observ
discontinu
csa
therapi
n
per
group
fischer
hess
figur
combin
effect
donor
recipi
age
induct
sgvhd
lewi
rat
mo
age
use
donor
marrow
recipi
either
mo
old
rat
mo
age
use
donor
marrow
graft
recipi
month
month
age
recipi
treat
mgkgd
c
observ
appear
sgvhd
discontinu
c
therapi
n
per
group
combin
effect
ofdonor
recipi
age
mgkg
dose
c
use
marrow
donor
recipi
either
mo
age
result
reveal
greatest
incid
sgvhd
csa
therapi
occur
marrow
deriv
donor
mo
age
dose
csa
sgvhd
induc
ofrat
mo
age
marrow
donor
mo
old
taken
togeth
result
present
fig
b
appear
recipi
age
variabl
overcom
increas
dose
csa
use
donor
marrow
deriv
younger
anim
contrast
marrow
deriv
donor
mo
age
moder
incid
sgvhd
occur
csa
therapi
enhanc
significantli
increas
dose
csa
effect
combin
unfraction
marrow
young
old
donor
incid
ofsyngen
gvhd
next
seri
experi
design
address
whether
mix
unfraction
marrow
anim
mo
age
could
modifi
incid
syngen
gvhd
normal
induc
bone
marrow
youngest
donor
alon
bone
marrow
donor
mo
age
transfus
first
alon
lethal
irradi
recipi
control
two
differ
dose
x
x
nucleat
cell
use
reconstitut
recipi
experiment
group
receiv
total
x
bone
marrow
cell
deriv
donor
mo
age
mix
equal
proport
recipi
receiv
csa
therapi
mgkgd
incid
ofsyngen
gvhd
observ
result
summar
tabl
recipi
bone
marrow
donor
mo
age
demon
wk
age
graft
syngen
bone
marrow
deriv
syngen
rat
mo
age
anim
mo
old
marrow
infus
singli
mix
recipi
treat
cours
csa
mgkgd
discontinu
csa
therapi
anim
observ
daili
appear
sgvhd
strate
sever
diseas
entir
experiment
group
least
day
discontinu
csa
therapi
receiv
x
develop
aggress
diseas
wk
earlier
receiv
x
cell
notabl
recipi
marrow
donor
mo
age
develop
diseas
reconstitut
x
cell
one
eight
rat
transfus
x
cell
develop
mild
sgvhd
recipi
x
cell
donor
combin
x
cell
donor
mo
age
demonstr
time
incid
clinic
sgvhd
receiv
marrow
matur
donor
alon
summari
transfus
marrow
matur
anim
influenc
potenti
bone
marrow
immatur
anim
induc
autoimmun
marrow
donor
mo
age
contain
popul
cell
capabl
prevent
induct
syngen
gvhd
secondari
recipi
matur
anim
modifi
induct
sgvhd
studi
describ
demonstr
marrow
matur
anim
modifi
induct
ofsgvhd
ad
marrow
inoculum
anim
mo
age
seri
experi
undertaken
identifi
character
cell
popul
respons
effect
marrow
lewi
rat
mo
age
separ
basi
size
densiti
counterflow
centrifug
elutri
techniqu
routin
use
cell
deplet
human
bone
marrow
recent
adapt
use
rat
allow
excel
recoveri
cell
small
lymphocyt
purg
flow
rate
mlmin
larger
lymphocyt
myeloid
cell
mlmin
clonogen
hemopoiet
blast
cell
collect
stop
rotor
thu
name
ro
fraction
initi
studi
compar
separ
characterist
marrow
lewi
rat
moder
increas
number
cell
isol
fraction
marrow
anim
compar
marrow
anim
mo
age
reflect
differ
yield
ro
fraction
fraction
ro
fraction
vs
respect
studi
perform
assess
given
fraction
marrow
donor
mo
age
respons
prevent
induct
sgvhd
marrow
lewi
rat
mo
age
elutri
ro
fraction
x
cell
fraction
transfus
x
x
unfraction
bone
marrow
cell
syngen
donor
lethal
irradi
recipi
wk
age
incid
ofsgvhd
recipi
record
csa
therapi
clinic
observ
sequenti
biopsi
time
autopsi
result
summar
tabl
marrow
harvest
lewi
rat
fraction
elutri
unfraction
marrow
respect
ro
elutri
fraction
x
cell
ad
marrow
deriv
syngen
lewi
rat
infus
lewi
rat
wk
age
control
recipi
receiv
either
marrow
rat
mo
age
elutri
fraction
separ
recipi
treat
cours
csa
therapi
mgkgd
observ
onset
sgvhd
marrow
donor
mo
age
result
five
eight
rat
develop
sgvhd
howev
sgvhd
occur
recipi
receiv
either
x
bone
marrow
cell
immatur
donor
x
elutri
bone
marrow
cell
isol
fraction
donor
mo
age
thu
fraction
potent
inhibitori
effect
prevent
ofsyngen
gvhd
addit
ofth
ro
andor
fraction
marrow
anim
unfraction
marrow
donor
mo
age
significantli
influenc
induct
ofsyngen
gvhd
furthermor
anim
graft
separ
ro
fraction
fraction
marrow
anim
mo
age
engraft
develop
sgvhd
cours
csa
mgkg
therapi
anim
engraft
fraction
use
singli
potent
capabl
ofunfraction
marrow
donor
mo
age
inhibit
primari
induct
syngen
gvhd
marrow
immatur
anim
appear
isol
elutri
fraction
fraction
also
account
inabl
marrow
anim
mo
age
allow
induct
ofsgvhd
studi
fischer
hess
undertaken
phenotyp
character
cell
contain
fraction
marrow
matur
mo
immatur
mo
lewi
rat
singlecolor
flow
cytometr
analysi
demonstr
fraction
anim
mo
age
mean
three
experi
predomin
cell
matur
lymphocyt
marker
tabl
fraction
anim
cell
matur
cell
marker
predomin
b
cell
ox
cell
express
b
cell
also
express
also
signific
percentag
ofcel
stain
marker
greatest
differ
appear
reduc
number
cell
fraction
compar
marrow
ro
fraction
group
minim
total
cell
defin
stain
fraction
ro
furthermor
fraction
small
percentag
entir
elutri
marrow
experi
undertaken
assess
deplet
matur
cell
cell
express
marker
fraction
marrow
matur
lewi
rat
remov
abil
fraction
inhibit
induct
sgvhd
irradi
lewi
rat
wk
ofag
graft
marrow
donor
mo
age
unfraction
marrow
fraction
fraction
deplet
cell
cell
ad
deriv
anim
mo
age
recipi
anim
treat
standard
cours
csa
mgkgd
incid
sgvhd
observ
withdraw
ofcsa
therapi
result
tabl
show
deplet
matur
lymphocyt
remov
inhibitori
activ
fraction
induct
sgvhd
studi
show
deplet
ofeith
subset
alon
remov
inhibitori
effect
induct
sgvhd
howev
recombin
fraction
restor
inhibitori
activ
reflect
prevent
sgvhd
indic
subset
requir
marrow
lewi
rat
mo
age
also
contain
matur
cell
yet
allow
induct
sgvhd
marrow
harvest
lewi
rat
mo
age
fraction
elutri
fraction
lymphocyteenrich
fraction
deplet
cell
lymphocyt
cocktail
immunomagent
bead
unfraction
marrow
fraction
andor
deplet
fraction
mix
marrow
deriv
syngen
rat
mo
age
graft
irradi
lewi
recipi
wk
age
anim
treat
csa
mgkgd
observ
onset
sgvhd
discontinu
therapi
attempt
assess
abil
young
marrow
allow
induct
sgvhd
due
decreas
number
matur
cell
describ
due
absenc
ofspecif
regulatori
cell
resid
fraction
marrow
older
anim
doserespons
studi
perform
grade
dose
lymphocyt
fraction
marrow
lewi
rat
mo
age
infus
unfraction
marrow
anim
irradi
recipi
wk
age
recipi
treat
csa
mgkgd
incid
sgvhd
observ
result
tabl
demonstr
addit
x
cell
fraction
donor
mo
age
complet
abolish
induct
sgvhd
x
cell
reduc
incid
sgvhd
compar
even
addit
lymphocyt
fraction
marrow
anim
mo
age
inhibit
induct
sgvhd
similarli
addit
splenic
nylon
woolnonadher
lymphocyt
anim
mo
ofag
inoculum
marrow
prevent
develop
sgvhd
csa
therapi
hand
highest
dose
splenic
lymphocyt
donor
mo
age
inhibit
induct
sgvhd
role
host
resist
mechan
induct
sgvhd
seri
experi
undertaken
identifi
role
host
resist
mechan
prevent
induct
sgvhd
result
studi
describ
indic
addit
matur
lymphocyt
anim
mo
age
marrow
inoculum
graft
composit
time
transplant
prevent
develop
sgvhd
one
hypothesi
account
inhibit
develop
sgvhd
matur
lymphocyt
contain
marrow
spleen
expand
csa
therapi
level
capabl
prevent
express
ofth
autoreact
cell
gener
therapi
recent
data
suggest
matur
lymphocyt
expand
thymecand
antigenindepend
environ
assess
ifth
matur
lymphocyt
includ
cell
respons
host
resist
clonal
expand
thymectom
lewi
rat
graft
marrow
deplet
oft
lymphocyt
elutri
wk
transplant
recipi
infus
x
splenic
lymphocyt
nylon
woolnonadher
cell
treat
csa
mgkgd
control
diluent
therapi
recipi
infus
x
effector
lymphocyt
anim
activ
sgvhd
result
tabl
demonstr
sgvhd
could
transfer
bone
marrowreconstitut
thymectom
recipi
graft
x
lymphocyt
howev
sgvhd
could
transfer
recipi
treat
csa
due
primari
induct
sgvhd
sinc
control
thymectom
recipi
treat
csa
develop
diseas
thu
confirm
data
sorokin
et
al
data
suggest
csa
interfer
expans
lymphocytedepend
host
resist
mechan
carri
matur
lymphocyt
could
prevent
adopt
transfer
diseas
x
effector
cell
grade
dose
lymphocyt
fraction
elutri
marrow
nylon
woolnonadher
spleen
cell
deriv
lewi
rat
mo
age
ad
marrow
syngen
anim
number
cell
estim
express
immunofluoresc
stain
mixtur
cell
infus
irradi
syngen
lewi
recipi
wk
age
rat
treat
standard
cours
csa
therapi
mgkgd
anim
observ
onset
sgvhd
discontinu
csa
treatment
also
compar
efficaci
infus
matur
splenic
lymphocyt
anim
mo
age
either
day
transplant
day
withdraw
csa
therapi
day
result
summar
tabl
sgvhd
could
induc
lymphocyt
infus
day
oftranspl
howev
develop
ofsgvhd
observ
despit
infus
x
normal
splenic
lymphocyt
anim
mo
age
day
c
withdraw
data
suggest
frequenc
autoreact
lymphocyt
exceed
minimum
number
cell
regul
host
resist
mechan
transfer
x
normal
lymphocyt
assess
autoreact
cell
could
detect
anim
receiv
marrow
plu
matur
lymphocyt
time
transplant
seri
ofadopt
transfer
studi
perform
harvest
cell
day
csa
withdraw
sinc
csa
therapi
prevent
clonal
expans
host
resist
mechan
carri
matur
cell
marrow
inoculum
premis
experi
evalu
autoreact
potenti
lymphocyt
anim
graft
marrow
matur
cell
clonal
activ
due
presenc
c
subsequ
transfer
environ
reduc
absent
host
resist
mechan
transfer
splenocyt
x
c
treat
recipi
graft
marrow
plu
lymphocyt
anim
mo
age
harvest
day
secondari
recipi
result
adopt
transfer
diseas
howev
transfer
spleen
cell
x
csatreat
anim
graft
marrow
absenc
cell
result
develop
sgvhd
secondari
recipi
immunobiolog
mechan
account
induct
sgvhd
administr
ofcsa
syngen
bmt
inde
complex
remain
enigmat
central
peripher
lymphocyt
thymectom
lewi
rat
irradi
rad
reconstitut
syngen
marrow
deplet
lymphocyt
elutri
wk
transplant
recipi
infus
x
splenic
lymphocyt
rat
mo
age
anim
treat
csa
control
diluent
day
x
efector
cell
anim
activ
sgvhd
adopt
transfer
thymectom
recipi
grade
dose
splenic
lymphocyt
anim
mo
age
adopt
transfer
bone
marrow
deriv
anim
mo
age
reconstitut
syngen
lewi
recipi
day
transplant
last
day
cours
csa
therapi
autoaggress
syndrom
appear
enhanc
gener
autoreact
clone
enter
peripheri
essenti
elimin
ofa
host
resist
autoregulatori
mechan
modifi
action
autoreact
cell
previou
studi
clearli
identifi
three
import
element
necessari
induct
sgvhd
result
imbal
autoaggress
autoregulatori
suppress
first
csa
necessari
requir
induct
sgvhd
sinc
syndrom
occur
syngen
bmt
recipi
treat
drug
although
rare
except
note
second
radiat
also
appear
play
essenti
role
acceler
appear
diseas
cheney
sprent
glazier
et
al
report
normal
nontranspl
anim
treat
csa
develop
autoaggress
syndrom
even
treat
high
dose
csa
contrast
routin
induct
syngen
gvhd
wholebodi
irradi
syngen
bmt
csa
therapi
recent
data
suggest
absenc
ofradi
csa
must
administ
mo
induc
autoimmun
diseas
third
essenti
requir
intact
thymu
must
includ
field
irradi
shown
glazier
et
al
shield
thymu
totalbodi
irradi
result
failur
induc
syndrom
evid
import
pivot
role
intact
thymu
provid
sorokin
et
al
syngen
gvhd
could
induc
thymectom
anim
requir
intact
thymu
present
although
csa
treatment
radiat
intact
thymu
requir
success
induct
sgvhd
present
studi
demonstr
age
also
critic
variabl
involv
autoaggress
syndrom
virtual
incid
ofsgvhd
could
induc
anim
initi
transplant
treat
csa
begin
wk
age
thereaft
incid
ofsgvhd
decreas
dramat
increas
age
anim
invers
correl
age
success
induct
sgvhd
surpris
sinc
mani
murin
autoimmun
model
increas
age
correl
onset
diseas
invers
relationship
age
induct
autoimmun
csa
mice
recent
report
particular
import
studi
find
age
recipi
signific
variabl
age
marrow
donor
even
greater
effect
sgvhd
could
consist
induc
older
anim
marrow
deriv
anim
wk
age
marrow
donor
mo
age
older
effect
ofth
recipi
age
induct
ofsgvhd
appear
part
relat
thymic
function
matur
anim
rel
resist
csa
beschorn
et
al
recent
demonstr
correl
age
ofth
recipi
receiv
mediastin
radiat
concomit
csa
therapi
capac
thymu
regener
normal
histolog
integr
postcsa
withdraw
prolong
disappear
medulla
notabl
immatur
rat
matur
rat
associ
loss
medullari
epithelium
hassal
corpuscl
class
ii
antigen
express
matur
rat
promin
medulla
csa
therapi
henc
resist
thymic
involut
hassal
corpuscl
disappear
howev
medulla
still
fusiform
epithelium
dendrit
cell
mhc
class
ii
antigen
express
despit
csa
therapi
postul
loss
ofth
thymic
medulla
mark
reduct
mhc
class
ii
antigen
express
csa
treatment
result
abrog
ofclon
delet
mechan
emerg
ofselfreact
clone
rel
resist
thymic
medulla
matur
anim
effect
csa
subsequ
preserv
clonal
delet
mechan
may
account
decreas
abil
induc
sgvhd
anim
howev
present
exclud
resist
matur
anim
fact
due
abil
rapidli
regener
thymicdepend
host
resist
mechan
see
surpris
find
studi
incid
sgvhd
significantli
associ
age
ofth
marrow
donor
even
greater
effect
age
recipi
addit
age
recipi
becam
less
import
donor
marrow
deriv
youngest
anim
marrow
anim
mo
age
larg
extent
incap
ofpermit
induct
sgvhd
despit
age
recipi
contrast
sgvhd
could
consist
induc
even
matur
anim
provid
marrow
deriv
anim
wk
age
furthermor
mix
marrow
donor
mo
age
elicit
reduc
incid
sgvhd
mimick
obtain
marrow
deriv
rat
mo
age
data
implic
regulatori
effect
present
marrow
matur
anim
studi
demonstr
regulatori
effect
marrow
anim
mo
age
due
presenc
small
matur
lym
phocyt
deplet
lymphocyt
elimin
modifi
influenc
ofmarrow
deriv
matur
anim
induct
sgvhd
coinfus
marrow
rat
mo
age
support
regulatori
effect
matur
lymphocyt
find
celldeplet
marrow
matur
anim
abl
permit
develop
sgvhd
b
addit
splenic
lymphocyt
rat
marrow
anim
mo
old
prevent
induct
sgvhd
contrast
although
slightli
less
number
matur
lymphocyt
contain
marrow
immatur
anim
prevent
develop
ofsgvhd
doserespons
studi
clearli
suggest
regulatori
activ
absent
marrow
immatur
anim
present
low
frequenc
compar
regulatori
activ
splenic
lymphocyt
young
anim
induct
sgvhd
observ
higher
concentr
cell
much
lower
number
splenic
lymphocyt
anim
mo
age
requir
prevent
induct
sgvhd
taken
togeth
data
suggest
celldepend
regulatori
system
capabl
modifi
induct
sgvhd
develop
anim
matur
data
consist
observ
sakaguchi
sakaguchi
demonstr
administr
c
newborn
mice
induc
pleiomorph
organspecif
autoimmun
diseas
csa
treatment
also
note
far
effect
start
day
birth
rather
third
seventh
day
birth
even
higher
dose
protract
period
c
treatment
could
induc
autoimmun
adult
mice
sakaguchi
sakaguchi
attribut
effect
develop
autoregulatori
system
prevent
amplif
express
autoregulatori
clone
also
postul
csa
prevent
develop
autoregulatori
system
temporari
absenc
thymicdepend
regulatori
system
allow
differentiationactiv
autospecif
effector
cell
earli
studi
clearli
implic
role
host
resist
mechan
involv
control
c
ainduc
sgvhd
primari
evid
includ
find
sgvhd
could
transfer
irradi
secondari
recipi
normal
anim
csa
treatment
normal
anim
induc
sgvhd
syndrom
although
adopt
transfer
spleen
cell
irradi
secondari
recipi
result
develop
ofsyngen
gvhd
find
suggest
normal
anim
possess
radiationsensit
compon
regul
activ
autoreact
cell
thu
prevent
develop
autoimmun
gvhd
adopt
transfer
studi
laboratori
provid
evid
irradiationand
cyclophosphamidesensit
thymicdepend
system
play
major
role
prevent
sgvhd
furthermor
normal
splenic
lymphocyt
cotransf
autoimmun
effector
cell
prevent
develop
ofsyngen
gvhd
secondari
recipi
regulatori
effect
normal
splenic
lymphocyt
requir
collabor
cell
subset
find
compar
result
present
studi
impor
fischer
hess
tanc
find
adopt
transfer
host
resist
mechan
dose
depend
requir
twice
number
splenic
lymphocyt
sgvhd
effector
cell
contrast
present
studi
demonstr
addit
small
number
oft
lymphocyt
marrow
graft
initi
induct
phase
prevent
develop
sgvhd
mechan
wherebi
lymphocyt
matur
anim
inhibit
induct
sgvhd
unclear
one
possibl
matur
lymphocyt
contain
marrow
graft
expand
despit
presenc
csa
level
abl
modifi
action
autoreact
cell
produc
cours
csa
therapi
recent
evid
present
powri
mason
suggest
matur
cell
prolifer
thymicand
antigenindepend
environ
thymectom
host
reconstitut
celldeplet
marrow
present
studi
demonstr
thymectom
rat
reconstitut
celldeplet
marrow
infus
small
number
lymphocyt
resist
adopt
transfer
sgvhd
effector
splenocyt
wait
allow
expans
normal
cell
howev
administr
csa
period
prevent
expans
host
resist
mechan
sgvhd
success
transfer
clearli
indic
csa
prevent
expans
host
resist
mechan
limit
number
effector
cell
x
capabl
establish
diseas
anim
infus
x
normal
lymphocyt
day
c
withdraw
fail
prevent
develop
sgvhd
data
impli
number
autoreact
cell
gener
csa
therapi
exceed
capac
host
resist
mechan
contain
x
normal
lymphocyt
hand
minimum
number
normal
cell
x
requir
ad
marrow
inoculum
infus
day
transplant
prevent
develop
sgvhd
sinc
csa
administr
prevent
expans
host
resist
mechan
would
seem
like
host
resist
mechan
contain
matur
lymphocyt
popul
carri
marrow
graft
inactiv
autoreact
cell
gener
cours
csa
therapi
hypothesi
also
support
failur
adopt
transfer
sgvhd
anim
graft
marrow
plu
matur
lymphocyt
irradi
secondari
recipi
host
resist
mechan
elimin
failur
induc
sgvhd
anim
graft
marrow
plu
lymphocyt
matur
anim
due
delic
balanc
ofautoreact
host
resist
thu
maintain
activ
control
suppress
autoreact
cell
one
would
expect
abl
transfer
diseas
environ
reduc
absent
host
resist
shown
cheney
sprent
taken
togeth
seem
like
host
resist
mediat
lymphocyt
matur
anim
clonal
inactiv
autoreact
cell
inactiv
induct
ofdon
anergi
thought
major
mechan
control
autoreact
cell
escap
clonal
delet
mechan
thymu
